ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
$139.7M
Market Cap • 3/31/2025
2011
(14 years)
Founded
2020
(5 years ago)
IPO
NYSE
Listing Exchange
Epalinges
Headquarters
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!